Androgen suppression strategies for prostate cancer: is there an ideal approach? - Wikidata - wikimedia - TriplyDB

Androgen suppression strategies for prostate cancer: is there an ideal approach?

Androgen suppression strategies for prostate cancer: is there an ideal approach?

http://www.wikidata.org/entity/Q37850714

about

Efficacy of intermittent androgen deprivation therapy vs conventional continuous androgen deprivation therapy for advanced prostate cancer: a meta-analysis 5α-Reductase inhibition coupled with short off cycles increases survival in the LNCaP xenograft prostate tumor model on intermittent androgen deprivation therapy.Adoption of Intermittent Androgen Deprivation Therapy for Advanced Prostate Cancer: A Population Based Study in American Urology Practice.5α-reductase inhibition suppresses testosterone-induced initial regrowth of regressed xenograft prostate tumors in animal models Degarelix: a review of its use in patients with prostate cancer.Risks of Serious Toxicities from Intermittent versus Continuous Androgen Deprivation Therapy for Advanced Prostate Cancer: A Population Based Study.The language of prostate cancer treatments and implications for informed decision making by patients.

P2860

Q34133868-ACA66DC6-FBEA-47D8-A022-3EE517EFFAB0 Q35498903-AD7AB29F-DD84-485B-9144-67273C26CA15 Q36623249-3D1C3F43-6059-442D-82D0-9BD9FDCC11B6 Q36946035-5FFD9E01-E372-4882-B154-62A02643C006 Q38206404-A52EDA5C-462F-4646-A424-7CE0E08AA244 Q49204760-F26EC1D9-7B0B-4328-B63E-B2E4CAE95342 Q51340619-16C29F90-F72E-4F9C-A34B-7F755EDDC09B

P2860

Androgen suppression strategies for prostate cancer: is there an ideal approach?

http://www.wikidata.org/entity/Q37850714

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on June 2011

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Androgen suppression strategies for prostate cancer: is there an ideal approach?

@en

Androgen suppression strategies for prostate cancer: is there an ideal approach?

@nl

type

label

Androgen suppression strategies for prostate cancer: is there an ideal approach?

@en

Androgen suppression strategies for prostate cancer: is there an ideal approach?

@nl

prefLabel

Androgen suppression strategies for prostate cancer: is there an ideal approach?

@en

Androgen suppression strategies for prostate cancer: is there an ideal approach?

@nl

P1433

Q37850714-D7AADA52-84D6-48C8-8234-2A656FF9387D

P1476

Q37850714-2BD05DA1-D4A7-4AB1-A261-9E766C548A57

P2093

Q37850714-4BEB56CD-F9DC-4CBA-9F61-36C29AAC9CAF

Q37850714-789D3AD6-B18F-4D0F-AEF5-7B99637D83BF

Q37850714-EC553C93-AEBD-4A3C-8BBB-1BA4915BF2D1

P2860

Q37850714-02D0469E-B828-4FA8-97C8-509AE58FD1C3

Q37850714-15F3EC10-8BC2-40D2-B3E5-AAD9A4C9885A

Q37850714-17DA890E-745A-4BC4-98A4-FD8CCB114D73

Q37850714-2052D04D-666A-4B37-B8AD-214641EBFF6D

Q37850714-24DDA44D-06A9-48A9-8251-6A9EFD14DA9B

Q37850714-2AB2E909-7A24-4A64-8485-E3EC6B50E7F8

Q37850714-2F6D995C-92C9-4DEA-81E7-4C5D7BA26D23

Q37850714-2F83BEBF-2B70-4A78-B2D3-E3A55C774D45

Q37850714-48825781-76C3-463A-948A-A5F015DD7B16

Q37850714-48DE3F6F-50EE-4EE0-BD33-D470DEBB7BA5

P2888

Q37850714-29D34449-6D02-46E8-9CA0-3D94354CBF29

P304

Q37850714-E84E0FD3-AD2A-40E9-9A91-2E63F3C1EC02

P31

Q37850714-3B1F2124-E455-4894-8384-9AD80453795C

P356

Q37850714-F72E0CD0-9563-42BE-A4A4-93BD113706EC

P433

Q37850714-8D04422C-5C0F-4CD9-A7FA-011EFEBA9805

P478

Q37850714-D1DBC2FC-414D-4C80-97D7-59C0CDB4C35B

P577

Q37850714-C5B29A0C-C3BE-4D2B-BA61-27794B7DECA9

P5875

Q37850714-0187CFF3-EDD2-4922-B760-C28591F7E29F

P698

Q37850714-582623C0-978E-4718-AAB1-E7F879A4FA6E

P356

S11934-011-0178-0

P1433

Current urology reports

P1476

Androgen suppression strategies for prostate cancer: is there an ideal approach?

@en

P2093

Leonard G Gomella

http://www.w3.org/2001/XMLSchema#string

Matthew Ferroni

http://www.w3.org/2001/XMLSchema#string

Mohamed Ismail

http://www.w3.org/2001/XMLSchema#string

P2860

Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study

Cancer statistics, 2010

Phase II study of Dutasteride for recurrent prostate cancer during androgen deprivation therapy

Single-therapy androgen suppression in men with advanced prostate cancer: a systematic review and meta-analysis.

6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial.

The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer.

Should intermittent androgen deprivation be used in routine clinical practice?

Surgically managed lymph node-positive prostate cancer: does delaying hormonal therapy worsen the outcome?

Systematic review of early vs deferred hormonal treatment of locally advanced prostate cancer: a meta-analysis of randomized controlled trials.

International study into the use of intermittent hormone therapy in the treatment of carcinoma of the prostate: a meta-analysis of 1446 patients.

P2888

s11934-011-0178-0

P304

188-196

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S11934-011-0178-0

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

12

http://www.w3.org/2001/XMLSchema#string

P577

2011-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

50305248

http://www.w3.org/2001/XMLSchema#string

P698

21384154

http://www.w3.org/2001/XMLSchema#string